Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Date Insider Type Main position Quantity % Market Cap.
22/06/22 Free 111,193 0.2314%
19/01/21 Sell 2,000 0.0179%
19/01/21 Sell 1 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-.--% - - 817K
+0.11%-3.98%+13.89%-10.34% 66.25B
-0.12%+3.10%+40.83%+196.27% 52.86B
+0.51%+37.90%+37.90%+37.90% 43.01B
-1.86%-4.93%-56.15%-56.66% 39.52B
+1.46%-3.97%+53.17%-27.57% 29.19B
+0.78%+0.03%+65.07%+83.88% 23.13B
-1.81%-9.71%+64.46%-53.65% 23.04B
-1.30%-6.18%+3.94%+177.59% 20.48B
-1.04%+0.53%+69.40%+119.96% 16.6B
Average -7.77%-2.11%+32.50%+51.93% 34.9B
Weighted average by Cap. -0.23%-1.59%+26.31%+46.51%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
50
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SPEX Stock